Skip to main content
. 2017 Sep 11;37(1):128–138. doi: 10.1038/onc.2017.316

Figure 6.

Figure 6

KRAS signaling induces CDKN2B expression via TGFβ pathway. (a) Expression of oncogenic KRAS induced the expression of TGFβ1 and CDKN2B in HPDE6-C7 cell line quantified by real-time PCR. (b) KRAS increased the CDKN2B promoter activity, and the effect was inhibited by MEK inhibitor U0126. (c) The expression of CDKN2B induced by KRAS was abolished by TGFβ receptor kinase inhibitor SB431542. (d) Western blot analysis of TGFβ1, CDKN2B, p-ERK and ERK. (e) P15 promoter with mutated Smad-binding element (SBE) site lost promoter activity as shown by luciferase reporter assay. The value is presented as the mean±s.e.m. **P<0.01, ***P<0.001.